RTP Mobile Logo
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Non-Small Cell Lung Cancer (Webinar Video Proceedings)
Released May 2022

Featuring perspectives from Dr Edward Garon, Ms Kelly Goodwin, Ms Tara Plues and Dr Anne Tsao. Published May 19, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer.

    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-small cell lung cancer.


    • Acknowledge the FDA approval of adjuvant osimertinib for localized non-small cell lung cancer (NSCLC) harboring an EGFR mutation, and identify patients for whom treatment with this novel approach would be warranted.
    • Counsel patients with metastatic NSCLC and an EGFR mutation regarding available therapeutic considerations, explaining the relevance of mutation type, symptomatology, sites and extent of metastases and other factors.
    • Understand the biology of EGFR exon 20 insertion mutations, and evaluate how recently approved agents should be employed in the care of patients with these abnormalities.
    • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC.
    • Convey the clinical relevance of a positive ROS1 mutation test result to appropriate patients with NSCLC, and appreciate available clinical research findings demonstrating efficacy with approved and investigational agents.
    • Assess available research evidence with approved RET inhibitors, and use this information to educate appropriate patients with newly diagnosed or progressive NSCLC.
    • Evaluate published clinical trial findings supporting the FDA approval of novel MET inhibitors for metastatic NSCLC harboring a mutation that leads to MET exon 14 skipping, and identify patients who might benefit from these compounds.
    • Recognize common side effects associated with the various targeted agents employed in the management of NSCLC, and implement supportive management strategies to minimize and ameliorate these toxicities.
    • Recall other oncogenic pathways (eg, KRAS G12C, HER2) mediating the growth of tumors in unique patient subsets, and consider published and emerging data with commercially available and investigational agents exploiting these targets.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    This educational activity for 2.25 contact hours is provided by RTP during the period of May 2022 through May 2023.

    This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.

    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2022/NSCLC/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2022NSCLC/NCPD.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Edward B Garon, MD, MS
    Director, Thoracic Oncology Program
    Director, Signal Transduction and Therapeutics Research Program
    David Geffen School of Medicine at UCLA
    Jonsson Comprehensive Cancer Center
    Los Angeles, California

    Consulting Agreements: ABL Bio, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, Gilead Sciences Inc, GlaxoSmithKline, Lilly, Merck, Natera Inc, Novartis, Personalis Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Shionogi Inc, Xilio Therapeutics; Contracted Research: ABL Bio, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Thoracic Cancer Center
    Massachusetts General Hospital
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Tara Plues, APRN, MSN
    Hematology and Medical Oncology
    Cleveland Clinic
    Cleveland, Ohio

    No relevant conflicts of interest to disclose.

    Anne S Tsao, MD, MBA
    Vice President, Faculty and Academic Affairs
    Professor, Thoracic/Head and Neck Medical Oncology
    Clinical Medical Director ad Interim, Thoracic and Orthopaedic Center
    Director, Mesothelioma Program
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Epizyme Inc, Genentech, a member of the Roche Group, Huron, Lilly, Merck, Novartis, Roche Laboratories Inc, Seagen Inc, SELLAS Life Sciences, Takeda Pharmaceuticals USA Inc; Research Grant: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Epizyme Inc, Genentech, a member of the Roche Group, Lilly, Merck, Polaris Group, Seagen Inc, Takeda Pharmaceuticals USA Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Regeneron Pharmaceuticals Inc and Sanofi.

    Release date: May 2022
    Expiration date: May 2023

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):